Sanzyme Biologics Announces Additional Findings Supporting the Efficacy of Bacillus coagulans SNZ 1969® in Managing Irritable Bowel Syndrome
Hyderabad, India – 17 Mar 2025 – Sanzyme Biologics, a pioneer in probiotics, proudly announces the publication of a sub group analysis that reinforces the efficacy of Bacillus coagulans SNZ 1969® in managing irritable bowel syndrome (IBS). This new analysis of Gastrointestinal Symptom Rating Scale for IBS (GSRS-IBS), published in the International Journal of Basic & Clinical Pharmacology, provides deeper insights into the probiotic’s effectiveness in alleviating individual symptoms of IBS, further building on the findings of the original published study [2].
Study Overview
Conducted as a randomized, double-blind, placebo-controlled trial, the research examined 80 patients diagnosed with either constipation-predominant IBS (IBS-C) or diarrhea-predominant IBS (IBS-D). Participants received either Bacillus coagulans SNZ 1969 (500 million CFU) or a placebo twice daily for 60 days, with assessments conducted at baseline, day 30, day 60, and day 75.
The follow-up analysis focused on individual components of the Gastrointestinal Symptom Rating Scale for IBS (GSRS-IBS), allowing researchers to evaluate the probiotic’s impact on abdominal pain, bloating, constipation, diarrhea, and satiety.
Key Findings
Statistically Significant Symptom Reduction: Patients treated with Bacillus coagulans SNZ 1969 experienced substantial reductions in all five GSRS-IBS domains compared to the placebo group.
Sustained Relief: The beneficial effects of Bacillus coagulans SNZ 1969 persisted through day 75, suggesting long-term symptom relief beyond the intervention period of 60 days.
Subtype-Agnostic Benefits: Unlike conventional IBS treatments that often target specific subtypes, Bacillus coagulans SNZ 1969 demonstrated efficacy across IBS-C and IBS-D, providing an insight through holistic approach in IBS management and thus making it a promising universal probiotic for Irritable Bowel Syndrome.
Implications for IBS Management
These findings strengthen the growing body of evidence supporting probiotics as a viable therapeutic option for IBS. With conventional treatments often falling short due to side effects and limited efficacy, Bacillus coagulans SNZ 1969 offers a safe and effective alternative by modulating gut microbiota, improving intestinal barrier function, and reducing inflammation.
Dr. Kishan P. V., the corresponding author, stated, “The additional findings in sub group analysis provides valuable insights into how Bacillus coagulans SNZ 1969 addresses the complex symptomatology of IBS. The broad-spectrum relief observed across multiple domains highlights its potential as a game-changer in IBS management.
About Sanzyme Biologics
Sanzyme Biologics is a pioneer in probiotics and a leading biotechnology company specializing in the research, development, and production of probiotics for human, pet and animal health. With a commitment to scientific innovation and clinical validation, Sanzyme Biologics continues to advance gut health solutions for global market requirements.
For more information about Bacillus coagulans SNZ 1969 and our research, contact us.
References:
- Soman RJ, Soman D, Kishan PV, Gorantla SC. Individual component analysis of gastrointestinal symptom rating scale for irritable bowel syndrome in IBS patients treated with Bacillus coagulans SNZ 1969: additional findings from a randomized, double-blind, placebo-controlled study. Int J Basic Clin Pharmacol. 2025;14(2):290-294. DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20250491
- Soman RJ, Gorantla SC, Swamy MV. Evaluation of efficacy and safety of Bacillus coagulans SNZ 1969 supplementation for irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Int J Basic Clin Pharmacol. 2022;11(6):550-58.